(USD) | Dec 2022 | Q/Q |
---|---|---|
Revenue | 0 | -100% |
Operating Income | -85.6MM | +8% |
Operating Expenses | 79.5MM | +12% |
Net Income | -85.5MM | +8% |
R&D | 47.2MM | +9% |
G&A | 32MM | +17% |
Interest Expense | 0 | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The best-performing growth stocks returned up to 537% in the last year, dramatically better than the performance of the category's benchmark index.
Cabaletta Bio, Ambrx Biopharma, and American Coastal Insurance offer the best 1-year total returns for October.
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transact
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the second quarter, the strategy underperformed the Russell 2000 Growth Index and returned 2.50% (net), and the index return was 7.05%. Consumer Staples, Health Care, Industrials, and Information […]
PLANO, Texas, September 21, 2023--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company’s previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen").
Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) is possibly approaching a major achievement in its business, so we would...
As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3 billion in cash. Buying Reata Pharmaceuticals will accomplish a couple of things for Biogen. First, it'll gain control of Reata's newly approved drug Skyclarys, which is the only medicine approved to treat Friedreich's ataxia.
On September 5, 2023, Bhaskar Anand, the SVP, Chief Accounting Officer of Reata Pharmaceuticals Inc (NASDAQ:RETA), sold 406 shares of the company.
Biogen is acquiring Reata Pharmaceuticals with the help of a hefty loan, Novo Nordisk teams up with the Broad Institute and other life sciences news you may have missed.
Top growth stocks for September include Cabaletta Bio Inc., Reata Pharmaceuticals Inc., and MoonLake Immunotherapeutics.